2-(5-bromopyrimidin-2-yl)ethanol | 1240725-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(5-bromopyrimidin-2-yl)ethanol
• CAS: 1240725-44-3
• 化学式: C₆H₇BrN₂O
• 分子量: 203.038
• InChiKey: BOECUBXDOGXVBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(5-bromopyrimidin-2-yl)ethanol 在 咪唑 、 碘 、 caesium carbonate 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 ethyl 4-(5-bromopyrimidin-2-yl)-2-methyl-2-(methylsulfonyl)butanoate
  参考文献：
  名称：

  Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

  摘要：

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

  DOI：

  10.1021/jm2014875
• 作为产物：
  描述：

  2-(5-溴嘧啶-2-基)乙酸甲酯 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.0h， 以10%的产率得到2-(5-bromopyrimidin-2-yl)ethanol
  参考文献：
  名称：

  Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

  摘要：

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

  DOI：

  10.1021/jm2014875

文献信息

• [EN] INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASES MUTANTES, COMPOSITIONS ET PROCÉDÉS CORRESPONDANTS
  申请人：ISOCURE BIOSCIENCES INC

  公开号：WO2018118793A1

  公开（公告）日：2018-06-28

  The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

  该发明提供了用于治疗癌症或相关疾病或障碍的新型化合物，以及其制备和使用的药物组合物和方法。
• ANTIBACTERIAL COMPOUNDS
  申请人：Biota Europe Ltd

  公开号：EP2828257A1

  公开（公告）日：2015-01-28
• INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF
  申请人：Isocure Biosciences Inc.

  公开号：EP3555079A1

  公开（公告）日：2019-10-23
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：BIOTA EUROPE LTD

  公开号：WO2013138860A1

  公开（公告）日：2013-09-26

  The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositons comprising them and processes for their mancfacture.
• Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections
  作者：Justin I. Montgomery、Matthew F. Brown、Usa Reilly、Loren M. Price、Joseph A. Abramite、Joel Arcari、Rose Barham、Ye Che、Jinshan Michael Chen、Seung Won Chung、Elizabeth M. Collantes、Charlene Desbonnet、Matthew Doroski、Jonathan Doty、Juntyma J. Engtrakul、Thomas M. Harris、Michael Huband、John D. Knafels、Karen L. Leach、Shenping Liu、Anthony Marfat、Laura McAllister、Eric McElroy、Carol A. Menard、Mark Mitton-Fry、Lisa Mullins、Mark C. Noe、John O’Donnell、Robert Oliver、Joseph Penzien、Mark Plummer、Veerabahu Shanmugasundaram、Christy Thoma、Andrew P. Tomaras、Daniel P. Uccello、Alfin Vaz、Donn G. Wishka

  DOI：10.1021/jm2014875

  日期：2012.2.23

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.